Experts discuss various aspects of phytopharmaceutical industry in India

Jamia Hamdard, New Delhi in collaboration with CSIR-IIIM Jammu organized a session on ‘Phytopharmaceuticals: Development, Regulatory, IPR & Marketing Challenges’

0
223
Download PDF

New Delhi: The Department of Pharmacognosy & Phytochemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi in collaboration with the Indian Institute of Integrative Medicine (CSIR-IIIM) Jammu organized a one-day interactive session in its campus. The UGC-SAP sponsored event focussed on ‘Phytopharmaceuticals: Development, Regulatory, IPR & Marketing Challenges’ and discussed the developments milestones and technical aspects of Phytopharmaceuticals in India.

The session was inaugurated by Pro Vice-Chancellor of Jamia Hamdard University, Dr Ahmad Kamal and Chaired by Prof. Vidhu Aeri (HOD) Pharmacognosy and Phytochemistry, Jamia Hamdard University.

Prof. S.S Handa (Former Director, IIIM), Dr D B Narayana (Former Director – Regulatory Affairs- Uni Lever), Mr Amit Sharma, Director –  (Sanat Products Limited and Hindustan Herbals Limited) , Dr U V Babu (Himalayan Drug company), Dr Neeraj Tandon (Head – ICMR) and Dr B P Panda ( Jamia Hamdard) were amongst several others attended the session.

Many eminent serving/retired experts, technocrats, pharmacists, the top brass of phytopharma scientific fraternity across various departments like CDSCO, IPC, CSIR, DBT, AYUSH, and industry representatives participated in the deliberations.

The program focused on understanding the approach, bringing clarity and extending thrust on Phyto Pharmaceuticals in India.

Prof S S Handa mentioned the details and efforts taken into bringing a new category of Phytopharmaceuticals in Indian drug and Pharma system. Globally 30 percent of the drugs still are being made by using plants and nature has solutions to the unmet need of mankind. In addition to this, he mentioned that the Government is pro-natural product industry and has been keen to incentivize this sector. He proposed to have regular interactions between industry and academia so it brings other stakeholders and Summit Partners under a common pavilion in order to flourish phytopharma in India.

Dr D B Narayna highlighted the significance of plant-based drug and efforts taken by industry stalwarts to bring to the industry at this stage and current developments are still not satisfactory and he would like to see the first licensed phytopharmaceutical drug in India.

Mr Amit Sharma, Director Sanat Products Limited and Hindustan Herbals limited shared important updates in these areas on international business expansion plans, strategy and future prospects in Phytopharmaceuticals, Botanicals, food and dietary supplements and professed urgent on initiating sustainable practices on the usage of medicinal and aromatic plants.

Dr Mohd Aslam, Advisor, Department of Biotechnology talked about the initiatives and findings available from Government of India under various programs for the promotion and development of the phytopharma in India. He stressed on the need to submit a complete proposal with proper drafting.